CN105237380A - Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound - Google Patents
Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound Download PDFInfo
- Publication number
- CN105237380A CN105237380A CN201510686332.4A CN201510686332A CN105237380A CN 105237380 A CN105237380 A CN 105237380A CN 201510686332 A CN201510686332 A CN 201510686332A CN 105237380 A CN105237380 A CN 105237380A
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- preparation
- extract
- ovarian cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a triterpene compound used for treating ovarian cancer and a preparation method of the triterpene compound. The compound is reported for the first time, is a novel triterpene compound and can be obtained by extracting, separating and purifying dried roots of rubus parvifolius. In-vitro tests prove that the compound can inhibit the proliferation vitality of ovarian cancer SKOV3 cells and affect distribution of a cell period, tumor cells are retarded in the G0/G1 period, meanwhile phosphorylation of the tumor cells can be inhibited through combination of the compound with tyrosine kinase phosphorylation ATP combination sites of EGFR/HER2 receptors, and therefore expression of HER2 and P-HER2 protein can be down-regulated, cell apoptosis is induced, and drugs for treating ovarian cancer can be further developed.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, be specifically related to from the dry root of Rubus parvifolius, be separated obtain a kind of and there is triterpene compound for the treatment of ovarian cancer effect and preparation method thereof.
Background technology
Rubus parvifolius is In Guangdong Province common medicine among the people, calls She Pao le, red plum disappears, March steeps, ulls up seedling Fischer, Radix Rubi Parvifolii is careless, is the dry root of Rosaceae rubus Rubus parvifolius RubusparvifoliusL..This product is machaka, is born in hillside, roadside, wasteland shrubbery and thick grass, strong adaptability, aboundresources, widely distributed.As Guangdong native drug, mainly produce more with cities and counties such as the South Sea, Yangshan, Yunans.Rubus parvifolius has effect that is clearing heat and detoxicating, promoting blood circulation and removing blood stasis, synthetism myogenic, is widely used in the treatment of tcm clinical practice as diseases such as wound, cold, fever, osteoma, nasopharyngeal carcinoma, pyelonephritis, acute pharyngolaryngitises.
In recent years, domestic and international researcher has obtained certain progress to the research of Rosaceae rubus, be separated the compound obtained and mainly contain terpene, flavonoid, sterols and volatile oil, lipid acid, aromatic acid, phenolic acid, tannin etc., wherein triterpenes pharmacologically active is comparatively strong, is prevalent in rubus.
Rubus parvifolius the most strikingly its pharmacologically active in cardiovascular systems that document is recorded, the therapeutic action particularly in anti-cerebral ischemia.Supplement to the Herbal is recorded Rubus parvifolius and is had that hemostasis is invigorated blood circulation, effect of blood stasis removing analgesic, oral administration external application.Modern study shows, Rubus parvifolius has hemostasis and effect promoting blood circulation and removing blood stasis, and identical with the pharmacological action of the drug for invigorating blood circulation and eliminating stasis red sage root in cardiovascular disorder with remarkable therapeutic action.Rubus parvifolius, to cerebral ischemia re-pouring injured provide protection, is mainly reflected in Green Tea Extract, alleviates the neurotoxicity of intracellular calcium overload and excitatory amino acid, inhibited apoptosis and affects the expression etc. of associated protein.The research such as Zheng Zhen Xiao finds that Rubus parvifolius total saponins has good antitumor action to inside and outside melanoma, in certain dose-effect dependence, and can promote the apoptosis of melanoma cell.Rubus parvifolius can be used for the treatment of dysmenorrhoea clinically, points out it also to have certain effect at ease pain.In addition Rubus parvifolius also can prevent and treat lead poisoning, and the SOD that its extract can significantly raise in Lead-poisoning Rats serum is active, and reduces the content of MDA.
Resources of Rubus Parvifolius Linn enriches, widely distributed, has many-sided pharmacologically active.Modern pharmacological research shows, Rubus parvifolius has significant effect at cardiovascular systems and anti-tumor aspect, is expected to the new drug being developed to cardiovascular systems and anti-tumor aspect.
Summary of the invention
The object of this invention is to provide and a kind ofly from the dry root of Rubus parvifolius, be separated obtain a kind of there is triterpene compound for the treatment of ovarian cancer effect and preparation method thereof.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
There is the compound (I) of following structural formula,
The preparation method of described compound (I), comprise following operation steps: the dry root of Rubus parvifolius is pulverized by (a), extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 8 column volumes, then use 80% ethanol elution, 10 column volumes, collect 80% ethanol eluate, concentrating under reduced pressure obtains 80% ethanol elution thing medicinal extract; C in () step (b), 80% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 75:1,45:1,25:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,15:1 and 8:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 10 ~ 12 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
Further, described macroporous resin is D101 macroporous adsorbent resin.
Further, described alcohol heat reflux extracts the alcohol concn adopted is 75%.
A kind of pharmaceutical composition, the described compound (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
The application of described compound (I) in the medicine of preparation treatment ovarian cancer.
The application of described pharmaceutical composition in the medicine of preparation treatment ovarian cancer.
When the compounds of this invention is used as medicine, directly can uses, or use with the form of pharmaceutical composition.
This pharmaceutical composition contains the compounds of this invention (I) for the treatment of significant quantity, and all the other are acceptable on pharmacology, nontoxic to humans and animals and pharmaceutically acceptable carrier of inertia and/or vehicle.
Described pharmaceutically acceptable carrier or vehicle are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation assistant agent.Pharmaceutical composition of the present invention is used with the form of per weight dose.Medicine of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, dripping pill, micropill, suspensoid, emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into water-based or oily solution, aseptic powder injection, liposome or the emulsion etc. of sterilizing.
Accompanying drawing explanation
Fig. 1 is compound (I) structural formula;
Fig. 2 is that the theoretical ECD value of compound (I) compares with experiment ECD value.
Embodiment
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: compound (I) is separated preparation and structural identification
Reagent source: ethanol, sherwood oil, ethyl acetate, propyl carbinol, methylene dichloride are analytical pure, purchased from Shanghai Ling Feng chemical reagent company limited, methyl alcohol, analytical pure, purchased from Jiangsu Han Bang chemical reagent company limited.
Preparation method: the dry root (10kg) of Rubus parvifolius is pulverized by (a), (25L × 3 time) are extracted with 75% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste (3L), use sherwood oil (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated propyl carbinol (3L × 3 time) to extract successively, obtain petroleum ether extract, acetic acid ethyl ester extract (431g) and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract D101 macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 8 column volumes, use 80% ethanol elution, 10 column volumes again, collect 80% ethanol eluate, concentrating under reduced pressure obtains 80% ethanol elution thing medicinal extract (161g); C in () step (b), 80% ethanol elution medicinal extract purification on normal-phase silica gel is separated, successively with volume ratio be 75:1 (8 column volumes), the methylene chloride-methanol gradient elution of 45:1 (8 column volumes), 25:1 (8 column volumes), 15:1 (10 column volumes) and 1:1 (5 column volumes) obtains 5 components; D component 4 (52g) is separated further by purification on normal-phase silica gel in () step (c), successively with volume ratio be 20:1 (8 column volumes), the methylene chloride-methanol gradient elution of 15:1 (10 column volumes) and 8:1 (8 column volumes) obtains 3 components; E in () step (d), component 2 (26g) reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 10-12 column volume elutriant, elutriant concentrating under reduced pressure obtains pure compound (I) (37mg).
Structural identification: HR-ESIMS shows [M+Na]
+for m/z507.3512, can obtain molecular formula in conjunction with nuclear-magnetism feature is C
31h
48o
4, degree of unsaturation is 8.Hydrogen nuclear magnetic resonance modal data δ
h(ppm, DMSO-d
6, 600MHz): H-2 (6.06, d, J=9.8), H-3 (6.84, d, J=9.8), H-6 (2.74, dd, J=14.4, 7.7), H-6 (2.47, t, J=14.4), H-7 (1.72, m), H-7 (1.31, m), H-8 (2.15, dd, J=12.1, 2.7), H-11 (3.02, d, J=6.3), H-12 (1.89, dd, J=15.0, 6.4), H-12 (1.81, d, J=15.0), H-15 (1.23, m), H-15 (1.33, m), H-16 (1.71, m), H-16 (1.26, m), H-17 (1.41, m), H-18 (0.91, s), H-19 (2.95, d, J=14.3), H-19 (2.48, d, J=14.3), H-20 (1.55, m), H-21 (0.90, d, J=6.6), H-22 (3.47, d, J=10.3), H-23 (1.07, m), H-23 (1.29, m), H-24 (2.39, m), H-26 (4.64, s), H-27 (1.53, s), H-28 (0.80, s), H-29 (1.26, s), H-30 (1.18, s), H-31 (0.98, d, J=7.0), carbon-13 nmr spectra data δ
c(ppm, DMSO-d
6, 150MHz): 185.4 (C, 1-C), 124.3 (CH, 2-C), 157.5 (CH, 3-C), 40.1 (C, 4-C), 167.2 (C, 5-C), 29.3 (CH
2, 6-C), 24.8 (CH
2, 7-C), 48.2 (CH, 8-C), 63.1 (C, 9-C), 131.7 (C, 10-C), 61.2 (CH, 11-C), 34.0 (CH
2, 12-C), 45.1 (C, 13-C), 46.5 (C, 14-C), 34.1 (CH
2, 15-C), 26.9 (CH
2, 16-C), 40.1 (CH, 17-C), 14.4 (CH
3, 18-C), 30.2 (CH
2, 19-C), 42.3 (CH, 20-C), 10.8 (CH
3, 21-C), 70.2 (CH, 22-C), 33.9 (CH
2, 23-C), 37.5 (CH, 24-C), 148.3 (C, 25-C), 109.6 (CH
2, 26-C), 19.8 (CH
3, 27-C), 17.0 (CH
3, 28-C), 23.0 (CH
3, 29-C), 23.2 (CH
3, 30-C), 16.5 (CH
3, 31-C), carbon atom mark is see Fig. 1.
1hNMR composes display five methyl singlets, and two methyl are bimodal, a pair dibasic double bond Hydrogen Proton of cis, a terminal double link, and two contain oxygen methyne.
13cNMR composes display 31 carbon signals, is respectively seven methyl, eight methylene radical (is alkene carbon), (two containing oxygen methyne for eight methynes, two alkene carbon) and eight quaternary carbons (a ketone carbonyl, contains oxygen quaternary carbon, three alkene carbon).In HMBC spectrum, CH
3-29 (CH
3-30) and the dependency of C-3, C-4 and C-5 and H-2 and C-1, C-4 and C-10 show, ring A is that 1,2-bis-replaces-4,4-dimethyl-2,5-dienone parts.In HMBC spectrum, H
2-19 and C-1, C-10, C-5, C-9 and C-8; H
2-6 and the dependency of C-4, C-5, C-7, C-8 and C-10, and CH
2(6)-CH
2(7)-CH (8) spin system, shows that B ring is the suberane replaced.CH in being composed by HMBC
3-31 and the known C-24 position of dependency of C-23, C-24 and C-25 be connected with a methyl.In HMBC spectrum, CH
3-21 with C-22 and H-22 and C-21, C-23, and the dependency of C-24 shows that C-22 position is connected with a hydroxyl.In addition, CH
3-27 and the dependency of C-24, C-25 and C-26 show to there is double bond between C-25 and C-26.Comprehensive hydrogen spectrum, carbon spectrum, HMBC spectrum and NOESY spectrum, and document is about correlation type nuclear magnetic data, can substantially determine this compound as shown in Figure 1, steric configuration is determined further by ECD test, theoretical value and experimental value basically identical (Fig. 2).
Embodiment 2: compound (I) pharmacological action is tested
One, material and instrument
People's serous papillary cystenoma of ovary shape cystadenocarcinoma Cell line SKOV3 is provided by the Medical experimental center of Lanzhou University.General RPMI-1640 substratum (10% foetal calf serum) is cultivated.Compound (I) is made by oneself, and HPLC normalization method purity is greater than 98%.RPMI-1640 nutrient solution, tetramethyl-azo frustrate indigo plant (MTT), dimethyl sulfoxide (DMSO) (DMSO), L-glutaminate Ke Hao biotechnology company limited.Trypsinase is purchased from Sigma Co., USA.Foetal calf serum is purchased from Hangzhou Sijiqing Biological Engineering Material Co., Ltd..Ten Second Academys base sodium sulfonate (SDS) are purchased from Xi'an Zhou Ding biotechnology limited liability company.HER2 (FITC mark) is purchased from Beijing Bo Aosen Bioisystech Co., Ltd.Acidifying HER2 (FITC mark) is purchased from Beijing Bo Aosen Bioisystech Co., Ltd.Penicillin, Streptomycin sulphate are purchased from North China Pharmaceutical Factory.
CO
2incubator (Heraeus, BB5060UV), Germany inverted phase contrast microscope (OLYMPUS, CK-40), Japan fluorescent microscope (OLYMPUSOPTICAL, A × 80, Japan), Bechtop (Purifying Equipment Co., Ltd., Suzhou), enzyme micro-plate reader (BIO-TEK company, the U.S.), low-temperature and high-speed whizzer (Beckman-Coulter company, Germany), EpicsXL flow cytometer (Beckman-Coulter company, Germany), the automatic desk-top flash arrestor (Xinhua Medical Apparatus Co., Ltd. Shandong) of R-3850 type, DHG-9245A type electric heating constant-temperature blowing drying box (Shanghai-permanent Science and Technology Ltd.), KQ-250DB type numerical control ultrasonic cleaner (Kunshan Ultrasonic Instruments Co., Ltd.), digital display constant water bath box (Shanghai Mei Xiang Instrument Ltd.), BS400S electronic molecules balance (Beijing Sai Duolisi balance company limited), 08-2 constant temperature blender with magnetic force (Shanghai balance equipment factory), TDL-5 generic centrifuge (Anting Scientific Instrument Factory, Shanghai), cryogenic refrigerator (SANYO GS company), electronics ice making case (SANYO GS company), cell cryopreservation tube (Shanghai Sheng Gong biotechnology company limited), 96 orifice plates (Ke Hao biotechnology company limited).
Two, test method
1, cell cultures
1.1 cell recovery
Put into 37 DEG C of warm water immediately after being taken out from liquid nitrogen rapidly by cryopreservation tube, rock cryopreservation tube gently, frozen thing is dissolved as early as possible, put it in Bechtop, cell suspension in it is moved into centrifuge tube, then in centrifuge tube, adds 10 times of RPMI-1640 nutrient solutions (containing 10% calf serum), centrifugal, 800rpm/min, centrifugal 5 ~ 10min, abandons supernatant, adds the RPMI-1640 nutrient solution containing 10% calf serum in cell precipitation, jog is even, puts 37 DEG C, 5%CO
2cultivate in the incubator of concentration.And indicate Cell Name and date.
1.2 passages are cultivated
When SKOV3 cell grows to 80 ~ 90% culturing bottle, discard original nutrient solution, and wash twice with the PBS prepared; With the trysinization of 0.25%, observe under being placed on inverted microscope, when seeing that cell retraction, intercellular substance increase, form become bowlder and discard Digestive system, add in a certain amount of nutrient solution and trysinization liquid, and the cell digested is blown and beaten gently with suction pipe., make it depart from culturing bottle, the centrifugal 5min of 800rpm/min, abandons supernatant; On tally, carry out cell counting under microscope, go down to posterity in 1:3 ratio, divide and be filled in culturing bottle, continue to cultivate after again supplementing appropriate nutrient solution.Note strict aseptic technique, every day observation of cell growing state.
1.3 cell cryopreservation
The cell of taking the logarithm vegetative period is with centrifugal after the tryptic digestion of 0.25%, PBS washes 2 times, the centrifugal 5min of l000rpm on low speed centrifuge, abandon supernatant liquor, add the cells frozen storing liquid containing DMSO of 1mL precooling at-20 DEG C, moving in cryopreservation tube with after suction pipe piping and druming evenly, with putting into 4 DEG C of standing 30min after sealed membrane sealing mark, proceeding to-80 DEG C after-20 DEG C of placement 2h afterwards.The cell used in one month can be stored in-80 DEG C, should move in liquid nitrogen after long-term preserver 24h by-80 DEG C.The recovery of cell and the frozen principle that should follow are melted soon for freezing slowly.
2, tetramethyl-azo blue (MTT) experiment
(1), when selecting cell (the growth 80-90%) of logarithmic phase, with 0.25% pancreatin prepared, cell is disappeared.Change well, single cell suspension is made in piping and druming lightly, and the final cell concn of adjustment is 8 × 10
4/ mL; (2) get 3 96 orifice plates, each time point 1 plate, 100 μ L/ holes, every porocyte number is 10
4carry out grouping mark; (3) divide into groups after cell attachment, if blank group (not inoculating cell), control group (only containing equivalent solvent) and experimental group (add the compound (I) of different concns, its final concentration is respectively 0.1,1,10,20,30 and 60 μm of ol/L), often group establishes 6 multiple holes; (4) 37 DEG C, 5%CO
224,48 and 72h is cultivated respectively under condition; (5), after the time arrives, after sucking supernatant liquor, every hole adds the MTT10 μ L of 5g/L; (6) add 10 μ LDMSO after cultivating 4h, multi-functional microplate test macro measures each hole optical density(OD) OD value with 490nm wavelength; (7) medicine is to the calculating of cell inhibitory rate:
Inhibiting rate (%)=(cellular control unit number-experimental group cell count)/cellular control unit number × 100%.
Experiment at least in triplicate.
3, PI staining flow cytometry (FCM) detects cell cycle and apoptosis
(1) the SKOV3 cell of taking the logarithm vegetative period, first make single cell suspension with blowing and beating gently after the trysinization prepared, adjustment cell concn is 6 × 10
5/ mL; (2) with 6 × 10
5the density of/mL is inoculated in the culturing bottle of 50mL, in 37 DEG C, 5%CO
224h is cultivated in incubator; (3) after 24h by original nutrient solution sucking-off, add isodose (7.5mL), containing the nutrient solution of the compound (I) of different concns (0,10,20 and 30 μm of ol/L), continue at 37 DEG C, 5%CO
248h is cultivated in incubator; (4) collecting cell after 48h, makes single cell suspension, after being moved into centrifuge tube with blowing and beating gently after 0.25% trysinization, centrifugal with 1000r/min, centrifugal l0min, abandoning supernatant, and fix with the ice ethanol of 4 DEG C 70%, place the refrigerator overnight of 4 DEG C; (5) secondary daily phosphate buffered saline buffer PBS clean, centrifugal, detect after abandoning supernatant and add rnase (RNAase) 150 μ L and propidium iodide (PI) dye liquor 150 μ L, lucifuge dyeing 30min at ambient temperature, uses period profile and the apoptosis situation of flow cytomery cell.Test in triplicate, and application software is analyzed.
4, PI staining flow cytometry (FCM) detects the expression rate of HER2, P-HER2 albumen
(1) the SKOV3 cell of taking the logarithm vegetative period, first make single cell suspension with blowing and beating gently after 0.25% trysinization, adjustment cell concn is l × 10
6/ mL; (2) with l × 10
6the density of/mL is inoculated in the culturing bottle of 50mL, in 37 DEG C, 5%CO
224h is cultivated in incubator; (3) the original nutrient solution of sucking-off after 24h, the nutrient solution (control group) of the nutrient solution (experimental group) of compound (I) that add isodose (12.5mL), that containing concentration be 20 μm of ol/L and not drug containing, continues at 37 DEG C, 5%CO
248h is cultivated in incubator; (4) collecting cell after 48h, first moves into the nutrient solution in culturing bottle in centrifuge tube, then uses the tryptic digestion of 0.25%, and the cell in guarantee culturing bottle and nutritive medium all move into centrifuge tube, centrifugal by 1000r/min, l0min; (5) add PBS again by the centrifugal 10min of 1000 turns/min, repeat twice; (6) treat in test tube, there are 100 μ L samples, add HER2, P-HER2 antibody receptor (dissolve with the PBS of PH=7.4,0.01M, and press 1:60 dilution) of 30 μ LFITC marks to experimental group and control group respectively, hatch 30min for 4 DEG C; (7) cell washing lotion is added, 1200 turns/min, 10min low-temperature centrifugation, 2 times repeatedly, censorship after removal supernatant; (8) expression rate of HER2, P-HER2 albumen of flow cytomery SKOV3 cell.Above-mentioned experimental procedure in triplicate.
5, data analysis
Adopt the software of SPSS17.0 to carry out statistical analysis, represent with mean ± standard deviation (X ± s).Adopt one-way analysis of variance to compare measurement data, and compare employing LSD inspection between group between two, the comparison of rate adopts chi square test, is that difference has statistical significance with P<0.05.
Three, result and conclusion
1, MTT experiment result
All occur obvious cell inhibitory effect effect after the compound (I) of different concns acts on people's adenocarcinoma ovaries SKOV3 cell 24,48 and 72h, show as OD value (absorbance A570) and reduce, inhibiting rate raises; Result between different concns group is variant, and difference has statistical significance (P<0.05), also significant difference (P<0.05) is had different action time, show that compound (I) propagation to ovarian cancer SKOV3 cell is inhibited, and its inhibiting rate is concentration and time-dependent manner.Learnt by experimental result, when concentration is 20 μm of ol/L, effect is more satisfactory.The results are shown in Table 1.
2, PI staining flow cytometry (FCM) detects the result of cell cycle
The compound (I) choosing different concns (10,20,30 μm of ol/L) acts on SKOV348h, and experimental group comparatively control group compares G
0/ G
1cell quantity in increasing trend, and S phase and G
2/ M cell quantity is minimizing trend, and when being 20 μm of ol/L with compound (I) concentration, effect is the most obvious.Compared with control group, each experimental group has statistical significance (P<0.05).G after each experimental group effect 48h
0/ G
1cell quantity be respectively 10 μm of ol/L groups (60.707 ± 2.382), 20 μm of ol/L groups (69.611 ± 2.366), 30 μm of ol/L groups (61.099 ± 1.577), the analysis showed that 30 μm of ol/L groups are compared with 10 μm of ol/L, no significant difference (P=0.809), comparing difference between all the other each concentration groups all has statistical significance (P<0.05).After each experimental group effect 48h, the cell quantity of S phase is respectively l0 μm of ol/L group (24.254 ± 3.244), 20 μm of ol/L groups (19.468 ± 0.580), 30 μm of ol/L groups (17.743 ± 1.311), wherein 30 μm of ol/L groups are compared with 20 μm of ol/L groups, no significant difference (P=0.305), all the other each concentration groups compare difference statistical significance (P<0.05).G after each experimental group effect 48h
2the cell quantity of/M phase is respectively l0 μm of ol/L group (13.276 ± 0.658), 20 μm of ol/L groups (10.624 ± 0.483), 30 μm of ol/L (21.147 ± 2.865), and comparing difference between remaining each concentration group has statistical significance (P<0.05).It can thus be appreciated that the effect that the compound of 20 μm of ol/L (I) acts on SKOV348h is best, by cell-cycle arrest in G
0/ G
1phase, make it can not enter the S phase.The results are shown in Table 2 (note: compared with control group, equal P<0.05; * G
0/ G
1during the phase, 30 μm of ol/L groups are compared with 10 μm of ol/L groups, no significant difference (P=0.809), and during S phase, 30 μm of ol/L are compared with 20 μm of ol/L, no significant difference (P=0.305); All the other G
0/ G
1, S, G
2compare between each phase group of/M, equal P<0.05.)。
3, PI staining flow cytometry (FCM) detects the expression of HER2, P-HER2
The expression of flow cytomery SKOV3 cell HER2 and P-HER2 on its surface before and after application compound (I), learn that compound (I) action effect of 20 μm of ol/L is ideal from above-mentioned experimental result, therefore this step adopts compound (I) (20 μm of ol/L) to act on SKOV3 cell 48h, the change not obvious (P=0.13) of HER2 protein expression before and after result display application compound (I), and the expression of P-HER2 albumen has obvious difference (P<0.05).The results are shown in Table 3 (note: compared with control group, * P=0.13,
#p<0.05).
Conclusion, compound (I) can suppress the proliferation activity of ovarian cancer SKOV3 cell, and the result of this experiment MTT shows, and it affects the distribution of cell cycle, and tumour cell is arrested in G
0/ G
1phase, simultaneously by being combined with the tyrosine kinases phosphorylate ATP-binding site of EGFR/HER2 acceptor, suppress its phosphorylation, and then the expression of lowering HER2, P-HER2 albumen carrys out cell death inducing.
Table 1 different concns, the compound (I) of different action time are on the impact of SKOV3 cell
The compound (I) of table 2 different concns acts on the impact of SKOV3 cell 48h cell cycle distribution
The compound (I) of table 320 μm ol/L acts on the expression of HER2, P-HER2 after SKOV3 cell 48h
Embodiment 3
The preparation of tablet: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, vehicle is added, pelletizing press sheet than the ratio for 1:7 in itself and excipient weight.
Embodiment 4
Prepared by oral liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, oral liquid method for making makes oral liquid routinely.
Embodiment 5
The preparation of capsule or granule: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, add vehicle in itself and excipient weight than the ratio for 1:7, make capsule or granule.
Embodiment 6
The preparation of injection liquid: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, inject with water routinely, essence filter, injection liquid is made in embedding sterilizing.
Embodiment 7
The preparation of aseptic powder injection: by embodiment 1 method first obtained compound (I), and the salt utilizing organic acid to make as tartrate or citric acid or formic acid or oxalic acid etc., mineral acid example hydrochloric acid or sulfuric acid or phosphoric acid, be dissolved in sterile water for injection, stirring makes molten, filter with aseptic suction funnel, aseptic essence filter again, be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains powder injection.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (7)
1. there is the compound (I) of following structural formula,
2. the preparation method of compound according to claim 1 (I), it is characterized in that comprising following operation steps: the dry root of Rubus parvifolius is pulverized by (a), extract with 70 ~ 80% alcohol heat reflux, united extraction liquid, be concentrated into without alcohol taste, use sherwood oil, ethyl acetate and water saturated n-butanol extraction successively, obtain petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; Acetic acid ethyl ester extract macroporous resin removal of impurities in (b) step (a), first use 10% ethanol elution, 8 column volumes, then use 80% ethanol elution, 10 column volumes, collect 80% ethanol eluate, concentrating under reduced pressure obtains 80% ethanol elution thing medicinal extract; C in () step (b), 80% ethanol elution medicinal extract purification on normal-phase silica gel is separated, obtain 5 components successively with the methylene chloride-methanol gradient elution that volume ratio is 75:1,45:1,25:1,15:1 and 1:1; D in () step (c), component 4 is separated further by purification on normal-phase silica gel, obtain 3 components successively with the methylene chloride-methanol gradient elution that volume ratio is 20:1,15:1 and 8:1; E in () step (d), component 2 reverse phase silica gel of octadecylsilane bonding is separated, with the methanol aqueous solution isocratic elution that concentration expressed in percentage by volume is 70%, collect 10 ~ 12 column volume elutriants, elutriant concentrating under reduced pressure obtains pure compound (I).
3. the preparation method of compound according to claim 2 (I), is characterized in that: described macroporous resin is D101 macroporous adsorbent resin.
4. the preparation method of compound according to claim 2 (I), is characterized in that: it is 75% that described alcohol heat reflux extracts the alcohol concn adopted.
5. a pharmaceutical composition, is characterized in that: the compound according to claim 1 (I) wherein containing treatment significant quantity and pharmaceutically acceptable carrier.
6. the application of compound according to claim 1 (I) in the medicine of preparation treatment ovarian cancer.
7. the application of pharmaceutical composition according to claim 5 in the medicine of preparation treatment ovarian cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510686332.4A CN105237380A (en) | 2015-10-20 | 2015-10-20 | Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510686332.4A CN105237380A (en) | 2015-10-20 | 2015-10-20 | Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105237380A true CN105237380A (en) | 2016-01-13 |
Family
ID=55035256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510686332.4A Pending CN105237380A (en) | 2015-10-20 | 2015-10-20 | Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105237380A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105481874A (en) * | 2015-12-22 | 2016-04-13 | 陈杰 | Novel diterpene compound for treating ovarian cancer |
| CN105646642A (en) * | 2016-03-23 | 2016-06-08 | 钱浩 | Baclofen drug composition and application thereof in bone destructive diseases |
| CN105777682A (en) * | 2016-03-23 | 2016-07-20 | 钱浩 | Citicoline sodium medicine composition and pharmaceutical application of citicoline sodium medicine composition to preventing and treating ovarian cancer |
| CN106146291A (en) * | 2016-07-04 | 2016-11-23 | 郑飞珍 | A kind of new sesquiterpene carboxylic acid compound and preparation method thereof and medical usage |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010024930A2 (en) * | 2008-08-28 | 2010-03-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses therof |
| WO2014123900A1 (en) * | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
-
2015
- 2015-10-20 CN CN201510686332.4A patent/CN105237380A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010024930A2 (en) * | 2008-08-28 | 2010-03-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses therof |
| WO2014123900A1 (en) * | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105481874A (en) * | 2015-12-22 | 2016-04-13 | 陈杰 | Novel diterpene compound for treating ovarian cancer |
| CN105646642A (en) * | 2016-03-23 | 2016-06-08 | 钱浩 | Baclofen drug composition and application thereof in bone destructive diseases |
| CN105777682A (en) * | 2016-03-23 | 2016-07-20 | 钱浩 | Citicoline sodium medicine composition and pharmaceutical application of citicoline sodium medicine composition to preventing and treating ovarian cancer |
| CN106146291A (en) * | 2016-07-04 | 2016-11-23 | 郑飞珍 | A kind of new sesquiterpene carboxylic acid compound and preparation method thereof and medical usage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103936590B (en) | Diterpene-kind compound in Euphorbia and pharmaceutical composition thereof and its application in pharmacy | |
| CN105330717A (en) | Novel triterpenoid and preparation method and medical application thereof | |
| CN105330716A (en) | New withanolides compound, and preparation method and medical application thereof | |
| CN105153084A (en) | Novel diterpene compound as well as preparation method and medicinal application thereof | |
| CN105237380A (en) | Triterpene compound used for treating ovarian cancer and preparation method of triterpene compound | |
| CN105061197A (en) | Novel triterpene compound and preparation method and medical application of novel triterpene compound | |
| CN105481802A (en) | Clerodane diterpenoid compounds, and preparation method and medical application thereof | |
| CN105943532A (en) | Application of diterpenoid compound to preparation of medicament for treating liver cancer | |
| CN105218617A (en) | A kind of new triterpenoid and preparation method thereof and medicinal use | |
| CN105294665A (en) | Novel diterpene compound for neuroprotection | |
| CN105601695A (en) | Triterpenoid compound, preparation method and medical application in treatment of prostate cancer | |
| CN105367536A (en) | Novel iridoid and preparation method and medical application thereof | |
| CN105418539A (en) | New meroterpenoid compound as well as preparation method and pharmaceutical application thereof | |
| CN106008543A (en) | Novel diterpenoid compound and preparation method thereof | |
| CN105418545A (en) | Novel isocoumarin compound and preparation method and medical application thereof | |
| CN105130935A (en) | New diterpenoid compounds for treating ovarian cancer | |
| CN105294723A (en) | Diterpenoid compound for treating breast cancer and preparation method thereof | |
| CN105481876A (en) | Diterpene compound for treating ovarian cancer | |
| CN105481874A (en) | Novel diterpene compound for treating ovarian cancer | |
| CN105968158A (en) | Novel lanostane type triterpenoid and preparation method and medical application thereof | |
| CN106397369A (en) | Novel labdane-type diterpenoid compound, preparation method and application thereof, pharmaceutical composition and application of pharmaceutical composition | |
| CN105254497A (en) | Novel diterpenoid compound and preparation method and medical application thereof | |
| CN105523937A (en) | Diterpene compound with medical application and preparation method thereof | |
| CN106074499A (en) | The application in medicine of a kind of Crow alkane type diterpene-kind compound | |
| CN105198897A (en) | New kaurane diterpenoid compound, preparation method and medical application of compound in treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160113 |